← Mechanisms of action
TACSTD2
SINGLE PROTEINHomo sapiens
Preferred name: Tumor-associated calcium signal transducer 2 ChEMBL ↗
Linked proteins
Drugs acting on this target (39)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| 9mw2921 | Binding agent | experimental | mAb | TACSTD2 binding agent |
| bio-106 | Binding agent | experimental | mAb | TROP2 |
| datopotamab deruxtecan (Datroway) | Binding agent | approved | mAb | Tumor-associated calcium signal transducer 2 binding agent |
| fda018-adc | Binding agent | experimental | mAb | TROP2 |
| fz-ad004 | Binding agent | experimental | mAb | TACSTD2 binding agent |
| ga-nota-rt4 | Binding agent | experimental | Peptide | TACSTD2 binding agent |
| hs-20105 | Binding agent | experimental | mAb | TACSTD2 binding agent |
| ibi130 | Binding agent | experimental | mAb | TACSTD2 binding agent |
| lcb84 | Binding agent | experimental | mAb | TACSTD2 binding agent |
| mhb036c | Binding agent | experimental | mAb | TROP2 |
| sacituzumab govitecan (Trodelvy) | Binding agent | approved | mAb | TACSTD2 binding agent |
| sti-3258 | Binding agent | experimental | mAb | TROP2 |
| mt-302 | Immunity, passive | experimental | Cell therapy | TACSTD2 immunity, passive |
| t60c | Immunity, passive | experimental | Cell therapy | TACSTD2 immunity, passive |
| trop2-car-nk | Immunity, passive | experimental | Cell therapy | TACSTD2 immunity, passive |
| ak146d1 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| avzo-103 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| bat8003 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| bat8008 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| bl-m08d1 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| bnt325 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| datopotamab deruxtecan (Datroway) | Inhibitor | approved | mAb | TACSTD2 inhibitor |
| db-1305 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| dm001 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| esg401 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| esg406 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| ibi3014 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| js108 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| mdx2001 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| mk-2828 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| obi-902 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| obi-992 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| pbi-410 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| pf-06664178 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| sacituzumab govitecan (Trodelvy) | Inhibitor | approved | mAb | TACSTD2 inhibitor |
| sim0270 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| skb264 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| vbc103 | Inhibitor | experimental | mAb | TACSTD2 inhibitor |
| [68ga]ga-nota-t4 | Radiopharmaceutical | experimental | Small molecule | TACSTD2 radiopharmaceutical |